Optiscan Signs Know-How Agreement with Mayo Clinic
Highlights
-
Optiscan signs Know-How agreement with US-based
Mayo Clinic to develop new endomicroscopic imaging system - The companies will work together to co-develop technology for use in robotic surgery
- Co-development and clinical testing will commence with initial focus on robotic-assisted breast cancer surgery
-
Mayo Clinic will take a financial interest in Optiscan’s technology
The collaboration combines Optiscan’s engineering expertise in digital endomicroscopic hardware and software development with Mayo Clinic’s know-how in robotic surgery and quality patient care. The agreement, which covers a 24-month co-development plan, will bring together experts from both companies to develop a robot-compatible endomicroscopic imaging system with an initial focus on robotic-assisted breast cancer surgery.
Optiscan CEO and Managing Director, Dr
The robotic-assisted surgery market is experiencing significant growth and is expected to continue expanding driven by technological advancements, increasing adoption, rising prevalence of chronic diseases, an aging population, surgeon demand, and favourable reimbursement policies. The US robotic surgery service market was valued at
This announcement has been authorised for release by the
About Optiscan
We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.
Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.
To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.
To learn more about
Disclaimer
All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate”, “believe”, “could”, “estimate”, “expect”, “future”, “intend”, “may”, “opportunity”, “plan”, “potential”, “project”, “seek”, “will” and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513411030/en/
For further information:
Shareholder & General Enquiries
Dr
M: +61 3 9538 3333
E: ceo@optiscan.com
Media & Investor Enquiries
The Capital Network
M: +61 2 8999 3699
E: russell@thecapitalnetwork.com.au
Source: